The team of physicians at Northeast Radiation Oncology Center (NROC) offers cancer patients in Northeastern Pennsylvania the opportunity to benefit from a state-of-the-art treatment known as radioisotope therapy. This treatment is effective for people experiencing bone pain as a result of their cancer spreading to the bone. It is one type of radiation treatment also known as “liquid radiation.”
Radioisotope therapy is a precisely targeted cancer treatment that delivers radioisotopes directly to cancerous cells in the bone, destroying the cancer and thus relieving the pain associated with the disease.
This specialized treatment is effective in relieving bone pain experienced by people whose prostate, breast, or other cancer has spread, or metastasized, to the bone. The Food and Drug Administration (FDA) has approved the treatment for patients whose metastatic bone lesions are evident on a bone scan.
Radioisotopes are delivered by injection into the patient’s blood stream. The blood system then carries the radioisotopes directly to bones throughout the body that are affected by the spreading cancer. There it precisely targets the cancer and emits radiation to kill the diseased cells, thereby relieving the pain caused by the cancer. The injection takes about one minute. Patients generally experience pain relief within one week.
Unlike opioids or other short-acting narcotic medications used to relieve pain, radioisotope treatment provides continuous pain relief for an average of 4 months. Up to 72% of the people who receive radioisotope therapy experience such pain relief. In addition, radioisotope treatment avoids some of the unwanted side effects that result from narcotic medications, such as drowsiness and constipation.
NROC in Dunmore and at Regional Hospital of Scranton are the only facilities in Northeastern Pennsylvania licensed to administer these stringently regulated radioisotope treatments. The therapy typically is administered on an outpatient basis.